Te­va and Xenon rack up an­oth­er set­back as PhI­Ib study fails on every end­point

The bad news is stack­ing up at Xenon Phar­ma­ceu­ti­cals. Its most ad­vanced drug just flopped in a Phase IIb at Te­va, just three months af­ter the biotech was forced to con­cede a stock-crunch­ing Phase II fail­ure for its in-house ac­ne drug.

Te­va and Xenon $XENE stuck with the top-line da­ta to­day, not­ing that test­ing TV-45070 in pa­tients with post-her­pet­ic neu­ral­gia failed at the pri­ma­ry as well as sec­ondary end­points. The fail­ure comes two years af­ter the same drug failed for os­teoarthri­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.